After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Rhythm Pharmaceuticals Inc. (RYTM) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.37, or -1.22%, to $29.90. The Rhythm Pharmaceuticals Inc. has recorded 7,558 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Rhythm Pharmaceuticals Announces New Employment Inducement Grants.
RYTM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $30.27 and fluctuated between $32.26 as its day high and $29.52 as its day low. The current market capitalization of Rhythm Pharmaceuticals Inc. is $1.73B. A total of 0.53 million shares were traded on the day, compared to an average of 630.73K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RYTM has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 2,500 shares. Over the last 12 months, there were 8 BUYs and 9 SELLs from insiders. Insiders purchased 52,089 shares during that period but sold 28,510.
In the most recent transaction, Cramer Pamela J. sold 13,493 shares of RYTM for 24.83 per share on Aug 19. After the transaction, the Chief Human Resources Officer now owns 2,224 company shares. In a previous transaction on Jul 27, Cramer Pamela J. sold 901 shares at 11.68 per share. RYTM shares that Chief Human Resources Officer owns now total 2,224.
Among the insiders who sold shares, Smith Hunter C disposed of 7,547 shares on Jul 01 at a per-share price of $4.08. This resulted in the Chief Financial Officer holding 57,614 shares of RYTM after the transaction. In another insider transaction, Roberts William T. sold 1,023 shares at $11.13 per share on Mar 29. Company shares held by the Chief Accounting Officer now total 1,477.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RYTM in the last 3 months, the mean price target is $33.67 with high estimates of $40.00 and low estimates of $26.00. In terms of 52-week highs and lows, RYTM has a high of $34.99 and a low of $3.04.
As of this writing, RYTM has an earnings estimate of -$1.01 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.86 per share and a lower estimate of -$1.08. The company reported an EPS of -$1.05 in the last quarter, which was -4.00% lower than expectations of -$1.01.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RYTM is Overweight with a score of 4.29. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.